John R Mascola Selected Research

Broadly Neutralizing Antibodies

1/2022	Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.
1/2022	A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination.
1/2022	Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.
1/2022	Antigenic analysis of the HIV-1 envelope trimer implies small differences between structural states 1 and 2.
1/2022	Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.
1/2022	First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody.
1/2022	Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.
1/2021	A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies.
1/2021	Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates.
1/2021	Blocking α4β7 integrin delays viral rebound in SHIVSF162P3-infected macaques treated with anti-HIV broadly neutralizing antibodies.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John R Mascola Research Topics

Disease

139	Infections 03/2022 - 05/2002
26	Human Influenza (Influenza) 01/2022 - 12/2011
24	COVID-19 04/2022 - 06/2020
17	Viremia 01/2022 - 10/2003
15	Acquired Immunodeficiency Syndrome (AIDS) 12/2021 - 12/2003
14	Virus Diseases (Viral Diseases) 03/2022 - 05/2002
14	HIV Infections (HIV Infection) 01/2022 - 11/2002
7	Communicable Diseases (Infectious Diseases) 01/2022 - 07/2005
5	Persistent Infection 01/2019 - 01/2015
4	Neoplasms (Cancer) 10/2017 - 08/2015
3	Pneumonia (Pneumonitis) 02/2021 - 07/2015
3	Zika Virus Infection 01/2020 - 01/2016
3	Ebola Hemorrhagic Fever 01/2017 - 04/2015
2	Headache (Headaches) 01/2022 - 10/2019
2	Equine Encephalomyelitis (Equine Encephalitis) 01/2022 - 01/2019
2	Malaria 03/2021 - 01/2021
2	Edema (Dropsy) 02/2021 - 01/2021
2	Body Weight (Weight, Body) 01/2021 - 10/2017
2	Syphilis 01/2019 - 11/2003
2	Superinfection 01/2019 - 01/2018
1	Coronavirus Infections 01/2022
1	Venezuelan Equine Encephalomyelitis 01/2022
1	Neutropenia 01/2022
1	Flavivirus Infections 11/2021
1	Asymptomatic Infections 11/2021
1	Weight Loss (Weight Reduction) 10/2021
1	Severe Acute Respiratory Syndrome 10/2021
1	Acute Lung Injury 10/2021
1	Parasitemia 01/2021
1	Inflammation (Inflammations) 10/2020
1	Myalgia 10/2019
1	Chills 10/2019
1	Viral Encephalitis 01/2019
1	Bites and Stings (Sting) 01/2019
1	Paramyxoviridae Infections (Parainfluenza) 11/2018

Drug/Important Bio-Agent (IBA)

94	VaccinesIBA 01/2022 - 11/2002
53	AntibodiesIBA 03/2022 - 05/2002
49	Broadly Neutralizing AntibodiesIBA 01/2022 - 11/2009
40	Neutralizing AntibodiesIBA 12/2021 - 05/2003
24	Monoclonal AntibodiesIBA 04/2022 - 10/2003
23	EpitopesIBA 03/2022 - 04/2005
18	Glycoproteins (Glycoprotein)IBA 10/2019 - 09/2009
17	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 10/2003
15	Hemagglutinins (Hemagglutinin)IBA 01/2022 - 09/2015
13	Antiviral Agents (Antivirals)IBA 01/2021 - 11/2006
11	AntigensIBA 12/2021 - 11/2002
10	Proteins (Proteins, Gene)FDA Link 12/2021 - 11/2002
9	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2022 - 12/2011
7	Immunoglobulins (Immunoglobulin)IBA 01/2020 - 04/2009
6	2019-nCoV Vaccine mRNA-1273IBA 11/2021 - 06/2020
6	AIDS VaccinesIBA 01/2017 - 07/2009
5	RNA (Ribonucleic Acid)IBA 01/2022 - 05/2009
5	Bispecific AntibodiesIBA 10/2021 - 01/2017
5	Polysaccharides (Glycans)IBA 01/2020 - 01/2016
4	Peptides (Polypeptides)IBA 04/2022 - 01/2013
3	Immunoglobulin G (IgG)IBA 11/2019 - 01/2013
3	Indicators and Reagents (Reagents)IBA 10/2017 - 08/2005
3	DNA VaccinesIBA 09/2015 - 07/2005
3	Viral RNAIBA 07/2011 - 11/2003
2	DH1047IBA 01/2022 - 04/2021
2	aluminum sulfate (alum)IBA 01/2022 - 10/2021
2	Biological Warfare AgentsIBA 01/2022 - 02/2015
2	bamlanivimabIBA 12/2021 - 10/2020
2	CytokinesIBA 02/2021 - 01/2021
2	Blocking AntibodiesIBA 02/2021 - 01/2021
2	Fc Receptors (Fc Receptor)IBA 02/2021 - 01/2021
2	Immunoglobulin A (IgA)IBA 11/2019 - 01/2013
2	Ferritins (Ferritin)IBA 01/2019 - 11/2018
2	peptide AIBA 01/2018 - 01/2018
2	Cell Surface ReceptorsIBA 10/2016 - 07/2014
2	Inactivated VaccinesIBA 09/2015 - 08/2013
2	env Gene ProductsIBA 04/2015 - 06/2006
2	GP 140IBA 07/2011 - 04/2009
2	EnzymesIBA 07/2008 - 11/2002
2	ImmunosorbentsIBA 07/2008 - 11/2002
1	Viral ProteinsIBA 01/2022
1	Vorinostat FDA Link 01/2022
1	mRNA VaccinesIBA 12/2021
1	Messenger RNA (mRNA)IBA 12/2021
1	Protein Subunit VaccinesIBA 10/2021
1	keyhole-limpet hemocyanin (keyhole limpet hemocyanin)IBA 03/2021
1	NanovaccinesIBA 01/2021
1	CIS43LSIBA 01/2021
1	Antimalarials (Antimalarial Agents)IBA 01/2021
1	COVID-19 VaccinesIBA 06/2020
1	IgG Receptors (Fc gamma RI)IBA 01/2020
1	SqualeneIBA 01/2019
1	Toll-Like Receptor AgonistsIBA 01/2019
1	Virus-Like Particle VaccinesIBA 01/2019
1	Dihydrotachysterol (AT 10)IBA 10/2017
1	Adenosine Monophosphate (AMP)IBA 01/2017

Therapy/Procedure

14	Therapeutics 01/2022 - 02/2004
3	Aftercare (After-Treatment) 01/2022 - 08/2015
2	Highly Active Antiretroviral Therapy (HAART) 01/2016 - 10/2015
1	Drug Therapy (Chemotherapy) 01/2022
1	Injections 11/2021
1	Intramuscular Injections 11/2021
1	Intravenous Administration 10/2019
1	Art Therapy 01/2019
1	Intravenous Infusions 01/2017